Director Michael Purcell Buys $50K in Stock at 30x Current Market Price, Joining Insider Cluster
Summary
Director Michael J. Purcell purchased $50,000 of company stock at $0.04 per share, a price significantly above the current market value, as part of a broader insider buying trend.
Key Events
-
Director's Significant Stock Purchase
Director Michael J. Purcell acquired $50,000 worth of common stock, representing over 10% of the company's market capitalization.
-
Purchase at Substantial Premium
Shares were bought at $0.04 each, approximately 30 times higher than the current market price of $0.0013.
-
Part of Broader Insider Buying
This purchase is one of several recent insider transactions, including the Interim CEO and Executive Chairman, all buying at the $0.04 price, likely linked to a recent private placement.
Analysis
This Form 4 filing reveals Director Michael J. Purcell's significant open-market purchase of $50,000 worth of Hepion Pharmaceuticals common stock. This transaction is particularly notable as it represents over 10% of the company's current market capitalization and was executed at a price of $0.04 per share, which is approximately 30 times higher than the current stock price of $0.0013. This purchase is part of a cluster of insider buying, including the Interim CEO and Executive Chairman, all transacting at the same $0.04 price, likely related to the recent $700,000 private placement announced on April 22, 2026. Such a substantial investment at a significant premium to the market price signals strong conviction from the board regarding the company's future prospects, despite recent stock performance.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $476.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.